|Mr. Gregory F. Kowal||Chief Exec. Officer and Chief Exec. Officer of Consumer Products Division||N/A||N/A||68|
|Dr. Michael F. Corcoran Ph.D.||Pres and Director of Sales & Marketing||N/A||N/A||67|
|Mr. Lawrence Harris Wolfe||Chief Financial Officer, VP of Fin. and Director||N/A||N/A||54|
|Ms. Melanie K. Kelekolio||Gen. Mang. of The Operations & Production Facility and VP||N/A||N/A||49|
|Mr. Kenneth I. Crowder||Chief Operating Officer of the Consumer Products Division||N/A||N/A||78|
Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology. It produces various substances and bioactive compounds that have applications in a range of commercial areas, including human nutrition, pharmaceuticals, and other commodities, such as bio-diesel. The companys products include ASTAFACTOR, a nutraceutical and source of natural astaxanthin; SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids; and KONA SEA SALT. It markets its products to mass retail outlets in Hawaii through distribution arrangements with companies. The company also operates a chain of professional martial arts studios. Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Pembroke Pines, Florida.
Mera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.